Understanding CAI's Role in Cancer and Fibrosis (G762)

Target Name: CA4

NCBI ID: G762

Content of Review Report on CA4 Target / Biomarker

CA4

Understanding CAI's Role in Cancer and Fibrosis

Cancer-associated fibrosis (CAF) is a complex interplay between cancer cells and the immune system that results in the progressive loss of tissue and the development of invasive and metastatic diseases. Despite the significant impact of CAF on cancer patient outcomes, the underlying molecular mechanisms that drive this process are not well understood. The protein Calbindin (CAI) is one of the most well-known biomarkers for CAF and has been widely studied in the context of cancer diagnosis, prognosis, and treatment. In this article, we will explore the role of CAI as a drug target and its potential as a biomarker for the diagnosis and treatment of CAF.

CAI is a type-I transmembrane protein that is expressed in various tissues and cells, including epithelial, mesenchymal, and neural tissues. It is characterized by its ability to bind to and modulate the activity of several transcription factors, including nuclear factor NF-kappa-B, transforming growth factor (TGF-β), and colony growth factor (LGF). In addition to its role in transcription factor regulation, CAI is also involved in the regulation of cell adhesion, migration, and the formation of tissues and organs.

The most well-known function of CAI is its role in the regulation of fibrosis. Fibrosis is a complex process that involves the activation and proliferation of fibroblasts, the production of extracellular matrix (ECM) components, and the progressive loss of tissue.CAI has has been shown to play a critical role in the regulation of fibrosis by suppressing the activity of fibroblasts and promoting the production of anti-fibrotic cytokines.

In addition to its role in fibrosis, CAI has also been shown to be involved in the regulation of cancer progression.CAI has been shown to promote the migration of cancer cells by increasing the adhesion of cells to the ECM and decreasing the inhibition of cell adhesion factors. Additionally, CAI has also been shown to contribute to the development of cancer stem cells by promoting the self-renewal and plasticity of these cells.

The therapeutic potential use of CAI as a drug target is significant due to its involvement in multiple cellular processes that are associated with cancer. As a drug target, CAI can be targeted with small molecules, antibodies, or other therapeutic agents that can modulate its activity and improve the understanding of its role in cancer. For example, inhibitors of CAI have been shown to have anti-tumor effects in various models of cancer, including breast, colorectal, and pancreatic cancer.

In addition to its potential therapeutic uses, CAI is also a potential biomarker for the diagnosis and treatment of CAF. Fibrosis is a key biomarker for CAF and can be used as a diagnostic tool in combination with other clinical variables. For example, the level of CAI in tissues can be used as a predictor of survival in patients with CAF-related diseases. Additionally, the levels of CAI in patient samples can be used to identify potential biomarkers for the diagnosis of CAF.

In conclusion, CAI is a critical protein that is involved in the regulation of multiple cellular processes that are associated with cancer. Its role in the regulation of fibrosis and cancer progression makes it an attractive target for therapeutic intervention. The potential therapeutic uses of CAI are significant, as are its potential as a biomarker for the diagnosis and treatment of CAF. Further research is needed to fully understand the role of CAI in cancer and to develop effective therapeutic approaches that can benefit patients with CAF-related diseases.

Protein Name: Carbonic Anhydrase 4

Functions: Catalyzes the reversible hydration of carbon dioxide into bicarbonate and protons and thus is essential to maintaining intracellular and extracellular pH (PubMed:15563508, PubMed:17652713, PubMed:7625839, PubMed:16807956, PubMed:16686544, PubMed:17705204, PubMed:17127057, PubMed:17314045, PubMed:19186056, PubMed:19206230, PubMed:18618712). May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis (PubMed:15563508). It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid (PubMed:15563508)

The "CA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets